LOR-S03
- Generic Name
- LOR-S03
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Phase 1
Completed
- Conditions
- Non-small Cell Lung CancerCholangiocarcinomaMSI-H Colorectal CancerEsophageal CancerFallopian Tube CancerRenal Cell CarcinomaPrimary Peritoneal CarcinomaBreast CancerGastric CancerOvarian Cancer
- Interventions
- First Posted Date
- 2020-06-22
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Celldex Therapeutics
- Target Recruit Count
- 27
- Registration Number
- NCT04440943
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Duke Cancer Center, Durham, North Carolina, United States
🇺🇸Providence Portland Medical Center, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath